Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Accumulated Depreciation (2017 - 2025)

Perspective Therapeutics (CATX) has disclosed Accumulated Depreciation for 13 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 109.59% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, up 109.59% year-over-year, with the annual reading at $6.2 million for FY2025, 109.59% up from the prior year.
  • Accumulated Depreciation hit $6.2 million in Q4 2025 for Perspective Therapeutics, up from $5.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $8.3 million in Q3 2023 to a low of $15000.0 in Q4 2022.
  • Historically, Accumulated Depreciation has averaged $5.2 million across 5 years, with a median of $6.7 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation: crashed 99.8% in 2022 and later skyrocketed 4360.0% in 2023.
  • Year by year, Accumulated Depreciation stood at $7.4 million in 2021, then plummeted by 99.8% to $15000.0 in 2022, then surged by 4360.0% to $669000.0 in 2023, then surged by 342.45% to $3.0 million in 2024, then skyrocketed by 109.59% to $6.2 million in 2025.
  • Business Quant data shows Accumulated Depreciation for CATX at $6.2 million in Q4 2025, $5.2 million in Q3 2025, and $4.4 million in Q2 2025.